<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">avk</journal-id><journal-title-group><journal-title xml:lang="ru">Архивъ внутренней медицины</journal-title><trans-title-group xml:lang="en"><trans-title>The Russian Archives of Internal Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2226-6704</issn><issn pub-type="epub">2411-6564</issn><publisher><publisher-name>“SINAPS” LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20514/2226-6704-2020-10-4-254-261</article-id><article-id custom-type="elpub" pub-id-type="custom">avk-1070</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW ARTICLES</subject></subj-group></article-categories><title-group><article-title>Фактор роста соединительной ткани в норме и патологии</article-title><trans-title-group xml:lang="en"><trans-title>Connective Tissue Growth Factor in Normal and Pathological Processes</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4131-8432</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тополянская</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Topolyanskaya</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">sshekshina@yahoo.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения РФ (Сеченовский Университет), кафедра госпитальной терапии № 2</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical University (Sechenov University), RF Health Ministry, Hospital Therapy Department № 2</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>29</day><month>07</month><year>2020</year></pub-date><volume>10</volume><issue>4</issue><fpage>254</fpage><lpage>261</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Тополянская С.В., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Тополянская С.В.</copyright-holder><copyright-holder xml:lang="en">Topolyanskaya S.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.medarhive.ru/jour/article/view/1070">https://www.medarhive.ru/jour/article/view/1070</self-uri><abstract><p>В обзоре отражены современные представления о роли фактора роста соединител ьной ткани при различных физиологических и патологических процессах. Фактор роста соединительной ткани регулирует разнообразные клеточные функции, в том числе, пролиферацию, миграцию, адгезию, дифференцировку и синтез белков внеклеточного матрикса в клетках различных типов, а также участвует в более сложных биологических процессах ангиогенеза, хондрогенеза, остеогенеза, заживления ран, фиброза и онкогенеза. Повышенная экспрессия фактора роста соединительной ткани наблюдается при различных сердечно-сосудистых и онкологических заб олеваниях. В обзоре обсуждается также потенциальная роль этого фактора роста в регуляции процессов клеточного старения.</p></abstract><trans-abstract xml:lang="en"><p>Modern concepts about the role of connective tissue growth factor in various physiological and pathological processes are described in the review. Connective tissue growth factor regulates a variety of cellular functions, including proliferation, migration, adhesion, differentiation and synthesis of extracellular matrix proteins in cells of different types. This factor is also involved in more complex biological processes of angiogenesis, chondrogenesis, wound healing, fibrosis and oncogenesis. Increased expression of connective tissue growth factor is observed in different cardiovascular and oncological diseases. Potential role of this growth factor in regulation of cellular senescence and aging processes is also discussed.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>фактор роста соединительной ткани</kwd><kwd>фиброз</kwd><kwd>нефросклероз</kwd><kwd>хондрогенез</kwd><kwd>остеогенез</kwd><kwd>старение</kwd></kwd-group><kwd-group xml:lang="en"><kwd>connective tissue growth factor</kwd><kwd>fibrosis</kwd><kwd>nephrosclerosis</kwd><kwd>chondrogenesis</kwd><kwd>osteogenesis</kwd><kwd>aging</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Arnott J.A., Lambi A.G., Mundy C., et al. The role of connective tissue growth factor (CTGF/CCN2) in skeletogenesis. Critical Reviews in Eukaryotic Gene Expression. 2011;21(1):43-69. doi:10.1615/ CritRevEukarGeneExpr.v21.i1.40.</mixed-citation><mixed-citation xml:lang="en">Arnott J.A., Lambi A.G., Mundy C., et al. The role of connective tissue growth factor (CTGF/CCN2) in skeletogenesis. Critical Reviews in Eukaryotic Gene Expression. 2011;21(1):43-69. doi:10.1615/ CritRevEukarGeneExpr.v21.i1.40.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ponticos M. Connective tissue growth factor (CCN2) in blood vessels. Vascul. Pharmacol. 2013;58(3):189-93. doi: 10.1016/j. vph.2013.01.004.</mixed-citation><mixed-citation xml:lang="en">Ponticos M. Connective tissue growth factor (CCN2) in blood vessels. Vascul. Pharmacol. 2013;58(3):189-93. doi: 10.1016/j. vph.2013.01.004.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Rayego-Mateos S., Rodrigues-Díez R., Morgado-Pascual J.L., et al. Connective tissue growth factor is a new ligand of epidermal growth factor receptor. J. Mol. Cell Biol. 2013;5(5):323–35. doi:10.1093/jmcb/mjt030.</mixed-citation><mixed-citation xml:lang="en">Rayego-Mateos S., Rodrigues-Díez R., Morgado-Pascual J.L., et al. Connective tissue growth factor is a new ligand of epidermal growth factor receptor. J. Mol. Cell Biol. 2013;5(5):323–35. doi:10.1093/jmcb/mjt030.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Leask A. CCN2 in skin fibrosis. Methods Mol. Biol. 2017;1489:417–21. doi:10.1007/978-1-4939-6430-7_34.</mixed-citation><mixed-citation xml:lang="en">Leask A. CCN2 in skin fibrosis. Methods Mol. Biol. 2017;1489:417–21. doi:10.1007/978-1-4939-6430-7_34.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ponticos M., Holmes A.M., Shi-wen X., et al. Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen. Arthritis Rheum. 2009;60(7):2142-55. doi: 10.1002/art.24620.</mixed-citation><mixed-citation xml:lang="en">Ponticos M., Holmes A.M., Shi-wen X., et al. Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen. Arthritis Rheum. 2009;60(7):2142-55. doi: 10.1002/art.24620.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ungvari Z., Valcarcel-Ares M.N., Tarantini S., et al. Connective tissue growth factor (CTGF) in age-related vascular pathologies. GeroScience. 2017;39(5-6):491–8. doi:10.1007/s11357-017-9995-5.</mixed-citation><mixed-citation xml:lang="en">Ungvari Z., Valcarcel-Ares M.N., Tarantini S., et al. Connective tissue growth factor (CTGF) in age-related vascular pathologies. GeroScience. 2017;39(5-6):491–8. doi:10.1007/s11357-017-9995-5.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Branchetti E., Poggio P., Sainger R., et al. Oxidative stress modulates vascular smooth muscle cell phenotype via CTGF in thoracic aortic aneurysm. Cardiovasc. Res. 2013;100(2):316-24. doi: 10.1093/cvr/cvt205.</mixed-citation><mixed-citation xml:lang="en">Branchetti E., Poggio P., Sainger R., et al. Oxidative stress modulates vascular smooth muscle cell phenotype via CTGF in thoracic aortic aneurysm. Cardiovasc. Res. 2013;100(2):316-24. doi: 10.1093/cvr/cvt205.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Sachdeva J., Mahajan A., Cheng J., et al. Smooth muscle cellspecific haploinsufficiency restricts the progression of abdominal aortic aneurysm by modulating CTGF expression. PLoS ONE. 2017;12(5):e0178538. doi: 10.1371/journal.pone.0178538.</mixed-citation><mixed-citation xml:lang="en">Sachdeva J., Mahajan A., Cheng J., et al. Smooth muscle cellspecific haploinsufficiency restricts the progression of abdominal aortic aneurysm by modulating CTGF expression. PLoS ONE. 2017;12(5):e0178538. doi: 10.1371/journal.pone.0178538.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Meng Y., Tian C., Liu L., et al. Elevated expression of connective tissue growth factor, osteopontin and increased collagen content in human ascending thoracic aortic aneurysms. Vascular. 2014;22(1):20-7. doi: 10.1177/1708538112472282.</mixed-citation><mixed-citation xml:lang="en">Meng Y., Tian C., Liu L., et al. Elevated expression of connective tissue growth factor, osteopontin and increased collagen content in human ascending thoracic aortic aneurysms. Vascular. 2014;22(1):20-7. doi: 10.1177/1708538112472282.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Yao Y., Li B., Fu C., et al. Anti-connective tissue growth factor detects and reduces plaque inflammation in early-stage carotid atherosclerotic lesions. Nanomedicine Nanotechnology, Biol. Med. 2017;13(8):2385–94. doi: 10.1016/j.nano.2017.07.016.</mixed-citation><mixed-citation xml:lang="en">Yao Y., Li B., Fu C., et al. Anti-connective tissue growth factor detects and reduces plaque inflammation in early-stage carotid atherosclerotic lesions. Nanomedicine Nanotechnology, Biol. Med. 2017;13(8):2385–94. doi: 10.1016/j.nano.2017.07.016.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Tsoutsman T., Wang X., Garchow K., et al. CCN2 plays a key role in extracellular matrix gene expression in severe hypertrophic cardiomyopathy and heart failure. J. Mol. Cell. Cardiol. 2013; 62:164–78. doi: 10.1016/j.yjmcc.2013.05.019.</mixed-citation><mixed-citation xml:lang="en">Tsoutsman T., Wang X., Garchow K., et al. CCN2 plays a key role in extracellular matrix gene expression in severe hypertrophic cardiomyopathy and heart failure. J. Mol. Cell. Cardiol. 2013; 62:164–78. doi: 10.1016/j.yjmcc.2013.05.019.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Touvron M., Escoubet B., Mericskay M., et al. Locally expressed IGF1 propeptide improves mouse heart function in induced dilated cardiomyopathy by blocking myocardial fibrosis and SRF-dependent CTGF induction. DMM Dis. Model. Mech. 2012;5(4):481-481. doi: 10.1242/dmm.009456.</mixed-citation><mixed-citation xml:lang="en">Touvron M., Escoubet B., Mericskay M., et al. Locally expressed IGF1 propeptide improves mouse heart function in induced dilated cardiomyopathy by blocking myocardial fibrosis and SRF-dependent CTGF induction. DMM Dis. Model. Mech. 2012;5(4):481-481. doi: 10.1242/dmm.009456.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Wu C.K., Wang Y.C., Lee J.K., et al. Connective tissue growth factor and cardiac diastolic dysfunction: Human data from the Taiwan Diastolic Heart Failure Registry and molecular basis by cellular and animal models. Eur. J. Heart Fail. 2014;16(2):163–72. doi: 10.1002/ejhf.33.</mixed-citation><mixed-citation xml:lang="en">Wu C.K., Wang Y.C., Lee J.K., et al. Connective tissue growth factor and cardiac diastolic dysfunction: Human data from the Taiwan Diastolic Heart Failure Registry and molecular basis by cellular and animal models. Eur. J. Heart Fail. 2014;16(2):163–72. doi: 10.1002/ejhf.33.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Koshman Y.E., Patel N., Chu M., et al. Regulation of connective tissue growth factor gene expression and fibrosis in human heart failure. J. Card. Fail. 2013;19(4):283–294. doi: 10.1016/j.cardfail.2013.01.013.</mixed-citation><mixed-citation xml:lang="en">Koshman Y.E., Patel N., Chu M., et al. Regulation of connective tissue growth factor gene expression and fibrosis in human heart failure. J. Card. Fail. 2013;19(4):283–294. doi: 10.1016/j.cardfail.2013.01.013.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Gerritsen K.G., Falke L.L., van Vuuren S.H., et al. Plasma CTGF is independently related to an increased risk of cardiovascular events and mortality in patients with atherosclerotic disease: the SMART study. Growth Factors. 2016;34(3–4):149–58. doi: 10.1080/08977194.2016.1210142.</mixed-citation><mixed-citation xml:lang="en">Gerritsen K.G., Falke L.L., van Vuuren S.H., et al. Plasma CTGF is independently related to an increased risk of cardiovascular events and mortality in patients with atherosclerotic disease: the SMART study. Growth Factors. 2016;34(3–4):149–58. doi: 10.1080/08977194.2016.1210142.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Hunt K.J., Jaffa M.A., Garrett S.M., et al. Plasma connective tissue growth factor (CTGF/CCN2) levels predict myocardial infarction in the veterans affairs diabetes trial (VADT) cohort. Diabetes Care. 2018;41(4):840–6. doi: 10.2337/dc17-2083.</mixed-citation><mixed-citation xml:lang="en">Hunt K.J., Jaffa M.A., Garrett S.M., et al. Plasma connective tissue growth factor (CTGF/CCN2) levels predict myocardial infarction in the veterans affairs diabetes trial (VADT) cohort. Diabetes Care. 2018;41(4):840–6. doi: 10.2337/dc17-2083.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Gravning J., Gravning J., Ørn S., et al. Myocardial Connective Tissue Growth Factor (CCN2/CTGF) Attenuates Left Ventricular Remodeling after Myocardial Infarction. PLoS ONE. 2012;7(12):e52120. doi: 10.1371/journal.pone.0052120.</mixed-citation><mixed-citation xml:lang="en">Gravning J., Gravning J., Ørn S., et al. Myocardial Connective Tissue Growth Factor (CCN2/CTGF) Attenuates Left Ventricular Remodeling after Myocardial Infarction. PLoS ONE. 2012;7(12):e52120. doi: 10.1371/journal.pone.0052120.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Ritschel V., Shetelig C., Seljeflot I., et al. Evaluation of circulating levels of CCN2/connective tissue growth factor in patients with ST-elevation myocardial infarction. Scientific Reports. 2017;7(1):11945. doi: 10.1038/s41598-017-12372-w.</mixed-citation><mixed-citation xml:lang="en">Ritschel V., Shetelig C., Seljeflot I., et al. Evaluation of circulating levels of CCN2/connective tissue growth factor in patients with ST-elevation myocardial infarction. Scientific Reports. 2017;7(1):11945. doi: 10.1038/s41598-017-12372-w.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Chi H., Feng H., Shang X., et al. Circulating Connective Tissue Growth Factor Is Associated with Diastolic Dysfunction in Patients with Diastolic Heart Failure. Cardiology (Switzerland). 2019;143(3-4):77-84. doi: 10.1159/000499179.</mixed-citation><mixed-citation xml:lang="en">Chi H., Feng H., Shang X., et al. Circulating Connective Tissue Growth Factor Is Associated with Diastolic Dysfunction in Patients with Diastolic Heart Failure. Cardiology (Switzerland). 2019;143(3-4):77-84. doi: 10.1159/000499179.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Koitabashi N., Arai M., Niwano K., et al. Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure. Eur. J. Heart Fail. 2008;10(4):373-9. doi: 10.1016/j.ejheart.2008.02.011.</mixed-citation><mixed-citation xml:lang="en">Koitabashi N., Arai M., Niwano K., et al. Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure. Eur. J. Heart Fail. 2008;10(4):373-9. doi: 10.1016/j.ejheart.2008.02.011.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Ehnes M., Brueckmann M., Lang S., et al. Connective tissue growth factor (CTGF/CCN2): Diagnostic and prognostic value in acute heart failure. Clin. Res. Cardiol. 2014;103(2):107–16. doi: 10.1007/s00392013-0626-6.</mixed-citation><mixed-citation xml:lang="en">Ehnes M., Brueckmann M., Lang S., et al. Connective tissue growth factor (CTGF/CCN2): Diagnostic and prognostic value in acute heart failure. Clin. Res. Cardiol. 2014;103(2):107–16. doi: 10.1007/s00392013-0626-6.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Chen J.Q., Guo Y.S., Chen Q., et al. TGFβ1 and HGF regulate CTGF expression in human atrial fibroblasts and are involved in atrial remodelling in patients with rheumatic heart disease. J. Cell. Mol. Med. 2019;23(4):3032-9. doi: 10.1111/jcmm.14165.</mixed-citation><mixed-citation xml:lang="en">Chen J.Q., Guo Y.S., Chen Q., et al. TGFβ1 and HGF regulate CTGF expression in human atrial fibroblasts and are involved in atrial remodelling in patients with rheumatic heart disease. J. Cell. Mol. Med. 2019;23(4):3032-9. doi: 10.1111/jcmm.14165.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Ko W.C., Hong C.Y., Hou S.M., et al. Elevated expression of connective tissue growth factor in human atrial fibrillation and angiotensin II-treated cardiomyocytes. Circ. J. 2011;75(7):1592-600. doi: 10.1253/ circj.cj-10-0892.</mixed-citation><mixed-citation xml:lang="en">Ko W.C., Hong C.Y., Hou S.M., et al. Elevated expression of connective tissue growth factor in human atrial fibrillation and angiotensin II-treated cardiomyocytes. Circ. J. 2011;75(7):1592-600. doi: 10.1253/ circj.cj-10-0892.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Leeuwis J.W., Nguyen T.O., Theunissen M.G.J., et al. Connective tissue growth factor is associated with a stable atherosclerotic plaque phenotype and is involved in plaque stabilization after stroke. Stroke. 2010;41(12):2979-81. doi: 10.1161/STROKEAHA.110.589036.</mixed-citation><mixed-citation xml:lang="en">Leeuwis J.W., Nguyen T.O., Theunissen M.G.J., et al. Connective tissue growth factor is associated with a stable atherosclerotic plaque phenotype and is involved in plaque stabilization after stroke. Stroke. 2010;41(12):2979-81. doi: 10.1161/STROKEAHA.110.589036.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Gonzalez D., Brandan E. CTGF/CCN2 from Skeletal Muscle to Nervous System: Impact on Neurodegenerative Diseases. Molecular Neurobiology. Humana Press Inc., 2019;56(8):5911–6. doi: 10.1007/ s12035-019-1490-9.</mixed-citation><mixed-citation xml:lang="en">Gonzalez D., Brandan E. CTGF/CCN2 from Skeletal Muscle to Nervous System: Impact on Neurodegenerative Diseases. Molecular Neurobiology. Humana Press Inc., 2019;56(8):5911–6. doi: 10.1007/ s12035-019-1490-9.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Yoshino J., Patterson B.W., Klein S. Adipose Tissue CTGF Expression is Associated with Adiposity and Insulin Resistance in Humans. Obesity. 2019;27(6):957-62. doi: 10.1002/oby.22463.</mixed-citation><mixed-citation xml:lang="en">Yoshino J., Patterson B.W., Klein S. Adipose Tissue CTGF Expression is Associated with Adiposity and Insulin Resistance in Humans. Obesity. 2019;27(6):957-62. doi: 10.1002/oby.22463.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Tan J.T.M., McLennan S.V., Williams P.F., et al. Connective tissue growth factor/CCN-2 is upregulated in epididymal and subcutaneous fat depots in a dietary-induced obesity model. Am. J. Physiol. Endocrinol. Metab. 2013;304(12):E1291-E1302. https://doi. org/10.1152/ajpendo.00654.2012.</mixed-citation><mixed-citation xml:lang="en">Tan J.T.M., McLennan S.V., Williams P.F., et al. Connective tissue growth factor/CCN-2 is upregulated in epididymal and subcutaneous fat depots in a dietary-induced obesity model. Am. J. Physiol. Endocrinol. Metab. 2013;304(12):E1291-E1302. https://doi. org/10.1152/ajpendo.00654.2012.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Leung J.C.K., Chan L.Y.Y., Tam K.Y., et al. Regulation of CCN2/ CTGF and related cytokines in cultured peritoneal cells under conditions simulating peritoneal dialysis. Nephrol. Dial. Transplant. 2009;24(2):458–69. doi: 10.1093/ndt/gfn524.</mixed-citation><mixed-citation xml:lang="en">Leung J.C.K., Chan L.Y.Y., Tam K.Y., et al. Regulation of CCN2/ CTGF and related cytokines in cultured peritoneal cells under conditions simulating peritoneal dialysis. Nephrol. Dial. Transplant. 2009;24(2):458–69. doi: 10.1093/ndt/gfn524.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Slagman M.C.J., Nguyen T.Q., Waanders F., et al. Effects of antiproteinuric intervention on elevated Connective Tissue Growth Factor (CTGF/ CCN-2) plasma and urine levels in nondiabetic nephropathy. Clin. J. Am. Soc. Nephrol. 2011;6(8):1845–50. doi: 10.2215/CJN.08190910.</mixed-citation><mixed-citation xml:lang="en">Slagman M.C.J., Nguyen T.Q., Waanders F., et al. Effects of antiproteinuric intervention on elevated Connective Tissue Growth Factor (CTGF/ CCN-2) plasma and urine levels in nondiabetic nephropathy. Clin. J. Am. Soc. Nephrol. 2011;6(8):1845–50. doi: 10.2215/CJN.08190910.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Nguyen T.Q., Tarnow L., Andersen S., et al. Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy. Diabetes Care. 2006;29(1):83-8. doi: 10.2337/ diacare.29.01.06.dc05-1670.</mixed-citation><mixed-citation xml:lang="en">Nguyen T.Q., Tarnow L., Andersen S., et al. Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy. Diabetes Care. 2006;29(1):83-8. doi: 10.2337/ diacare.29.01.06.dc05-1670.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Jaffa A.A., Usinger W.R., Mchenry B., et al. Connective tissue growth factor and susceptibility to renal and vascular disease risk in type 1 diabetes. J. Clin. Endocrinol. Metab. 2008;93(5):1893-900. doi: 10.1210/jc.2007-2544.</mixed-citation><mixed-citation xml:lang="en">Jaffa A.A., Usinger W.R., Mchenry B., et al. Connective tissue growth factor and susceptibility to renal and vascular disease risk in type 1 diabetes. J. Clin. Endocrinol. Metab. 2008;93(5):1893-900. doi: 10.1210/jc.2007-2544.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Nguyen T.Q., Tarnow L., Jorsal A., et al. Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy. Diabetes Care. 2008;31(6):1177–82. doi: 10.2337/dc07-2469.</mixed-citation><mixed-citation xml:lang="en">Nguyen T.Q., Tarnow L., Jorsal A., et al. Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy. Diabetes Care. 2008;31(6):1177–82. doi: 10.2337/dc07-2469.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Toda N., Mukoyama M., Yanagita M., et al. CTGF in kidney fibrosis and glomerulonephritis. Inflamm. Regen. 2018;38 (1):1–8. doi: 10.1186/ s41232-018-0070-0.</mixed-citation><mixed-citation xml:lang="en">Toda N., Mukoyama M., Yanagita M., et al. CTGF in kidney fibrosis and glomerulonephritis. Inflamm. Regen. 2018;38 (1):1–8. doi: 10.1186/ s41232-018-0070-0.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Toda N., Mori K., Kasahara M., et al. Crucial Role of Mesangial Cell-derived Connective Tissue Growth Factor in a Mouse Model of Anti-Glomerular Basement Membrane Glomerulonephritis. Sci. Rep. 2017;7:1-16. doi: 10.1038/srep42114</mixed-citation><mixed-citation xml:lang="en">Toda N., Mori K., Kasahara M., et al. Crucial Role of Mesangial Cell-derived Connective Tissue Growth Factor in a Mouse Model of Anti-Glomerular Basement Membrane Glomerulonephritis. Sci. Rep. 2017;7:1-16. doi: 10.1038/srep42114</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Mizdrak M., Filipovic N., Vukojevic K., et al. Prognostic value of connective tissue growth factor and c-Myb expression in IgA nephropathy and Henoch-Schonlein purpura — A pilot immunohistochemical study. Acta Histochemica. 2020;122(2):151479. doi: 10.1016/j.acthis.2019.151479.</mixed-citation><mixed-citation xml:lang="en">Mizdrak M., Filipovic N., Vukojevic K., et al. Prognostic value of connective tissue growth factor and c-Myb expression in IgA nephropathy and Henoch-Schonlein purpura — A pilot immunohistochemical study. Acta Histochemica. 2020;122(2):151479. doi: 10.1016/j.acthis.2019.151479.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">den Hoedt C.H., van Gelder M.R., Grooteman M.P., et al. Connective Tissue Growth Factor Is Related to All-cause Mortality in Hemodialysis Patients and Is Lowered by On-line Hemodiaﬁltration: Results from the Convective Transport Study. Toxins. 2019;11(5):268. doi: 10.3390/toxins11050268.</mixed-citation><mixed-citation xml:lang="en">den Hoedt C.H., van Gelder M.R., Grooteman M.P., et al. Connective Tissue Growth Factor Is Related to All-cause Mortality in Hemodialysis Patients and Is Lowered by On-line Hemodiaﬁltration: Results from the Convective Transport Study. Toxins. 2019;11(5):268. doi: 10.3390/toxins11050268.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Vanhove T., Kinashi H., Nguyen T.G., et al. Tubulointerstitial expression and urinary excretion of connective tissue growth factor 3 months after renal transplantation predict interstitial fibrosis and tubular atrophy at 5 years in a retrospective cohort analysis.Transpl. Int. 2017;30(7):695–705. doi: 10.1111/tri.12960.</mixed-citation><mixed-citation xml:lang="en">Vanhove T., Kinashi H., Nguyen T.G., et al. Tubulointerstitial expression and urinary excretion of connective tissue growth factor 3 months after renal transplantation predict interstitial fibrosis and tubular atrophy at 5 years in a retrospective cohort analysis.Transpl. Int. 2017;30(7):695–705. doi: 10.1111/tri.12960.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Jang J.H., Chand H.S., Bruse S., et al. Connective Tissue Growth Factor Promotes Pulmonary Epithelial Cell Senescence and Is Associated with COPD Severity. COPD J. Chronic Obstr. Pulm. Dis. 2017;14(2):228–37. doi: 10.1080/15412555.2016.1262340.</mixed-citation><mixed-citation xml:lang="en">Jang J.H., Chand H.S., Bruse S., et al. Connective Tissue Growth Factor Promotes Pulmonary Epithelial Cell Senescence and Is Associated with COPD Severity. COPD J. Chronic Obstr. Pulm. Dis. 2017;14(2):228–37. doi: 10.1080/15412555.2016.1262340.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Lipson K.E., Wong C., Teng Y., et al. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair. 2012;5(Suppl 1):S24. doi: 10.1186/1755-1536-5-S1-S24.</mixed-citation><mixed-citation xml:lang="en">Lipson K.E., Wong C., Teng Y., et al. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair. 2012;5(Suppl 1):S24. doi: 10.1186/1755-1536-5-S1-S24.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Richeldi L., Fernández Pérez E.R., Costabel U., et al. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2020;8(1):25–33. doi: 10.1016/S2213-2600(19)30262-0.</mixed-citation><mixed-citation xml:lang="en">Richeldi L., Fernández Pérez E.R., Costabel U., et al. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2020;8(1):25–33. doi: 10.1016/S2213-2600(19)30262-0.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Wang X., Cui H., Wu S. CTGF: A potential therapeutic target for Bronchopulmonary dysplasia. European Journal of Pharmacology.2019;860:172588. doi: 10.1016/j.ejphar.2019.172588.</mixed-citation><mixed-citation xml:lang="en">Wang X., Cui H., Wu S. CTGF: A potential therapeutic target for Bronchopulmonary dysplasia. European Journal of Pharmacology.2019;860:172588. doi: 10.1016/j.ejphar.2019.172588.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Xie Y., Wang Y., Liu K., et al. Correlation analysis between mechanical power, transforming growth factor-b1, and connective tissue growth factor levels in acute respiratory distress syndrome patients and their clinical signiﬁcance in pulmonary structural remodeling. Medicine. 2019;98(29):e16531. doi: 10.1097/MD.0000000000016531.</mixed-citation><mixed-citation xml:lang="en">Xie Y., Wang Y., Liu K., et al. Correlation analysis between mechanical power, transforming growth factor-b1, and connective tissue growth factor levels in acute respiratory distress syndrome patients and their clinical signiﬁcance in pulmonary structural remodeling. Medicine. 2019;98(29):e16531. doi: 10.1097/MD.0000000000016531.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Song Z.M., Liu F., Chen Y-M., et al. CTGF-mediated ERK signaling pathway inﬂuences the inﬂammatory factors and intestinal ﬂora in ulcerative colitis. Biomedicine &amp; Pharmacotherapy. 2019;111:1429–37. doi: 10.1016/j.biopha.2018.12.063.</mixed-citation><mixed-citation xml:lang="en">Song Z.M., Liu F., Chen Y-M., et al. CTGF-mediated ERK signaling pathway inﬂuences the inﬂammatory factors and intestinal ﬂora in ulcerative colitis. Biomedicine &amp; Pharmacotherapy. 2019;111:1429–37. doi: 10.1016/j.biopha.2018.12.063.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Wells J.E., Howlett M., Cole C.H., et al. Deregulated expression of connective tissue growth factor (CTGF/CCN2) is linked to poor outcome in human cancer. International Journal of Cancer. Wiley-Liss Inc. 2015;137(3):504–11. doi: 10.1002/ijc.28972.</mixed-citation><mixed-citation xml:lang="en">Wells J.E., Howlett M., Cole C.H., et al. Deregulated expression of connective tissue growth factor (CTGF/CCN2) is linked to poor outcome in human cancer. International Journal of Cancer. Wiley-Liss Inc. 2015;137(3):504–11. doi: 10.1002/ijc.28972.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Li X.T., Li J.Y., Zeng G.C., et al. Overexpression of connective tissue growth factor is associated with tumor progression and unfavorable prognosis in endometrial cancer. Cancer Biomark. 2019;25(4):295302. doi: 10.3233/cbm-190099.</mixed-citation><mixed-citation xml:lang="en">Li X.T., Li J.Y., Zeng G.C., et al. Overexpression of connective tissue growth factor is associated with tumor progression and unfavorable prognosis in endometrial cancer. Cancer Biomark. 2019;25(4):295302. doi: 10.3233/cbm-190099.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Shimbo A., Kajiyama H., Tamauchi S., et al. Expression of connective tissue growth factor as a prognostic indicator and its possible involvement in the aggressive properties of epithelial ovarian carcinoma. Oncol Rep. 2019;42(6):2323-2332. doi: 10.3892/ or.2019.7352.</mixed-citation><mixed-citation xml:lang="en">Shimbo A., Kajiyama H., Tamauchi S., et al. Expression of connective tissue growth factor as a prognostic indicator and its possible involvement in the aggressive properties of epithelial ovarian carcinoma. Oncol Rep. 2019;42(6):2323-2332. doi: 10.3892/ or.2019.7352.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Kubota S., Takigawa M. Cellular and molecular actions of CCN2/CTGF and its role under physiological and pathological conditions.Clin. Sci. Portland Press Ltd. 2014;128(3):181–96. doi: 10.1042/CS20140264</mixed-citation><mixed-citation xml:lang="en">Kubota S., Takigawa M. Cellular and molecular actions of CCN2/CTGF and its role under physiological and pathological conditions.Clin. Sci. Portland Press Ltd. 2014;128(3):181–96. doi: 10.1042/CS20140264</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Tomita N., Hattori T., Itoh S., et al. Cartilage-specific over-expression of CCN family member 2/connective tissue growth factor (CCN2/ CTGF) stimulates insulin-like growth factor expression and bone growth. PLoS One. 2013;8(3):e59226. doi: 10.1371/journal. pone.0059226</mixed-citation><mixed-citation xml:lang="en">Tomita N., Hattori T., Itoh S., et al. Cartilage-specific over-expression of CCN family member 2/connective tissue growth factor (CCN2/ CTGF) stimulates insulin-like growth factor expression and bone growth. PLoS One. 2013;8(3):e59226. doi: 10.1371/journal. pone.0059226</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Itoh S., Hattori T., Tomita N., et al. CCN Family Member 2/Connective Tissue Growth Factor (CCN2/CTGF) Has Anti-Aging Effects That Protect Articular Cartilage from Age-Related Degenerative Changes. PLoS One. 2013;8(8):1–2. doi: 10.1371/journal.pone.0071156</mixed-citation><mixed-citation xml:lang="en">Itoh S., Hattori T., Tomita N., et al. CCN Family Member 2/Connective Tissue Growth Factor (CCN2/CTGF) Has Anti-Aging Effects That Protect Articular Cartilage from Age-Related Degenerative Changes. PLoS One. 2013;8(8):1–2. doi: 10.1371/journal.pone.0071156</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Tang X., Muhammad H., McLean C., et al. Connective tissue growth factor contributes to joint homeostasis and osteoarthritis severity by controlling the matrix sequestration and activation of latent TGFβ. Ann. Rheum. Dis. 2018;77 (9):1372–80. doi: 10.1136/ annrheumdis-2018-212964</mixed-citation><mixed-citation xml:lang="en">Tang X., Muhammad H., McLean C., et al. Connective tissue growth factor contributes to joint homeostasis and osteoarthritis severity by controlling the matrix sequestration and activation of latent TGFβ. Ann. Rheum. Dis. 2018;77 (9):1372–80. doi: 10.1136/ annrheumdis-2018-212964</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Xu B., Wang X., Wu C., et al. Flavonoid compound icariin enhances BMP-2 induced differentiation and signalling by targeting to connective tissue growth factor (CTGF) in SAMP6 osteoblasts. PLoS ONE. 2018;13(7):e0200367. doi: 10.1371/journal.pone.0200367</mixed-citation><mixed-citation xml:lang="en">Xu B., Wang X., Wu C., et al. Flavonoid compound icariin enhances BMP-2 induced differentiation and signalling by targeting to connective tissue growth factor (CTGF) in SAMP6 osteoblasts. PLoS ONE. 2018;13(7):e0200367. doi: 10.1371/journal.pone.0200367</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Sun W., Ma J., Zhao H., et al. Resolvin D1 suppresses pannus formation via decreasing connective tissue growth factor caused by upregulation of miRNA146a-5p in rheumatoid arthritis. Arthritis Research &amp; Therapy.2020; 22(1):61. doi: 10.1186/s13075-020-2133-2.</mixed-citation><mixed-citation xml:lang="en">Sun W., Ma J., Zhao H., et al. Resolvin D1 suppresses pannus formation via decreasing connective tissue growth factor caused by upregulation of miRNA146a-5p in rheumatoid arthritis. Arthritis Research &amp; Therapy.2020; 22(1):61. doi: 10.1186/s13075-020-2133-2.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Bassyouni I.H., Mohammed W.H.S., Taha F.M. Clinical significance of CCN2/connective tissue growth factor in Behçet’s disease patients. Int J Rheum Dis. 2019;22(8):1459-65. doi: 10.1111/1756-185X.13597.</mixed-citation><mixed-citation xml:lang="en">Bassyouni I.H., Mohammed W.H.S., Taha F.M. Clinical significance of CCN2/connective tissue growth factor in Behçet’s disease patients. Int J Rheum Dis. 2019;22(8):1459-65. doi: 10.1111/1756-185X.13597.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Quan T., Shao Y., He T., et al. Reduced expression of connective tissue growth factor (CTGF/CCN2) mediates collagen loss in chronologically aged human skin. J. Invest. Dermatol. 2010;130(2):415–24. doi: 10.1038/jid.2009.224</mixed-citation><mixed-citation xml:lang="en">Quan T., Shao Y., He T., et al. Reduced expression of connective tissue growth factor (CTGF/CCN2) mediates collagen loss in chronologically aged human skin. J. Invest. Dermatol. 2010;130(2):415–24. doi: 10.1038/jid.2009.224</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">van Almen G.C., Verhesen W., van Leeuwen R.E.W., et al. MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. Aging Cell. 2011;10 (5):769-79. doi: https:// doi.org/10.1111/j.1474-9726.2011.00714.x</mixed-citation><mixed-citation xml:lang="en">van Almen G.C., Verhesen W., van Leeuwen R.E.W., et al. MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. Aging Cell. 2011;10 (5):769-79. doi: https:// doi.org/10.1111/j.1474-9726.2011.00714.x</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Jun J.I.I., Lau L.F. CCN2 induces cellular senescence in fibroblasts. J. Cell Commun. Signal. Springer Netherlands. 2017;11(1):15–23. doi: 10.1007/s12079-016-0359-1</mixed-citation><mixed-citation xml:lang="en">Jun J.I.I., Lau L.F. CCN2 induces cellular senescence in fibroblasts. J. Cell Commun. Signal. Springer Netherlands. 2017;11(1):15–23. doi: 10.1007/s12079-016-0359-1</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
